Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1613 1616 1617 1626
This examiner grants 48% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17831796 | Oral Care Products and Methods | Non-Final OA | BASF SE |
| 17635734 | STABILIZER CONCENTRATES FOR WAX DISPERSIONS | Final Rejection | BASF SE |
| 18613671 | METHOD FOR COATING PHARMACEUTICAL SUBSTRATES | Non-Final OA | Applied Materials, Inc. |
| 19016307 | PHARMACEUTICAL COMPOSITIONS FOR IMPROVING INTESTINAL BACTERIAL FLORA AND RELATED TREATMENT METHODS | Non-Final OA | Murata Manufacturing Co., Ltd. |
| 17592169 | BIOMIMETIC TISSUE AND METHOD OF USE THEREOF | Non-Final OA | New York University |
| 19048816 | GINGEROL COMPOSITIONS AND RELATED METHODS | Non-Final OA | ThermoLife International, LLC |
| 18318242 | PLASMA RADICAL SOLUTION AND METHOD FOR PREPARING SAME | Final Rejection | AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION |
| 18263420 | METHOD FOR PREPARING PROTEIN MICROBEADS FOR IMPROVING STABILITY OF PROTEIN PREPARATION | Non-Final OA | DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION |
| 18205399 | Hemostatic Foam | Non-Final OA | STRYKER EUROPEAN OPERATIONS HOLDINGS LLC |
| 18963743 | METHOD FOR TREATING METABOLIC DISORDERS BY ILEUM-TARGETED DELIVERY OF ENDOTOXIN SEQUESTRANT | Non-Final OA | SQ BIOPHARMA INC. |
| 18246239 | PARENTERAL NUTRITION FORMULATION COMPRISING VITAMIN B12 | Final Rejection | BAXTER HEALTHCARE SA |
| 18639302 | BIOCOMPATIBLE POLYMER AND MAGNESIUM FOR REGENERATION OF ARTICULAR SURFACES IN THE TEMPOROMANDIBULAR JOINT | Non-Final OA | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION |
| 17906514 | CONTINUOUS MELT-COATING OF ACTIVE PHARMACEUTICAL INGREDIENTS USING SURFACTANTS FOR DISSOLUTION ENHANCEMENT | Non-Final OA | Rutgers,The State University of New Jersey |
| 18723272 | LIPIDS FOR DRUG DELIVERY, NANOPARTICLES COMPRISING SAME, AND COMPOSITION FOR DRUG DELIVERY COMPRISING NANOPARTICLES | Non-Final OA | SAMYANG HOLDINGS CORPORATION |
| 18278279 | DICLOFENAC-CONTAINING PATCH PACKAGE PRODUCT AND METHOD FOR STABILIZING DICLOFENAC SODIUM | Non-Final OA | HISAMITSU PHARMACEUTICAL CO., INC. |
| 18631588 | CLEVIDIPINE EMULSION FORMULATIONS CONTAINING ANTIMICROBIAL AGENTS | Non-Final OA | CHIESI FARMACEUTICI S.P.A. |
| 18636564 | CARTILAGE GRAFT SCAFFOLDS | Non-Final OA | Trauma Care Consult Traumatologische Forschung Gemeinnützige Gesellschaft mbH |
| 18700024 | NANOPARTICULATE FORMULATION | Non-Final OA | NewImmune II, LLC |
| 18695943 | NEGATIVELY CHARGED PARTICLES FOR THE TREATMENT OF INFLAMMATION-RELATED BURN INJURIES | Non-Final OA | onCour Pharma, Inc. |
| 18595716 | Solid Solution Compositions and Use in Severe Pain | Non-Final OA | Infirst Healthcare Limited |
| 18282412 | FUNCTIONALIZED CHITOSAN PREPARATION | Non-Final OA | Firmenich SA |
| 18273710 | NALTREXONE COMPOSITIONS | Final Rejection | LDN Pharma Limited |
| 18467283 | MICROSPHERE FORMULATIONS COMPRISING NALTREXONE AND METHODS FOR MAKING AND USING THE SAME | Non-Final OA | Oakwood Laboratories, LLC |
| 18244882 | ORAL PHARMACEUTICAL COMPOSITION AND METHOD FOR PRODUCING PARTICULATE FORMULATION COMPRISING COMPOSITION | Final Rejection | Sunsho Pharmaceutical Co., Ltd. |
| 18244141 | INJECTABLE MELPHALAN COMPOSITIONS COMPRISING A CYCLODEXTRIN DERIVATIVE AND METHODS OF MAKING AND USING THE SAME | Non-Final OA | Cydex Pharmaceuticals, Inc. |
| 18278153 | SODIUM BICARBONATE INJECTABLE FORMULATION AND METHODS THEREOF | Final Rejection | Endo Operations Limited |
| 18546142 | An Oral Insulin Delivery Salt Nano-Precipitate | Final Rejection | MONASH UNIVERSITY MAYALSIA |
| 18352132 | DIALYSATE FOR HEMODIALYSIS | Non-Final OA | NIHON TRIM CO., LTD. |
| 18273990 | IMPLANTABLE MATERIAL IN CONTACT WITH BLOOD AND USES THEREOF | Final Rejection | UNIVERSITE DE GENEVE |
| 18262232 | CARTILAGE TISSUE ENGINEERING COMPLEX AND USE THEREOF | Final Rejection | SHANGHAI RESTHETIC BIO CO., LTD |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy